Roflumilast is a phosphodiesterase-4 (PDE4) inhibitor used for the treatment of COPD and plaque psoriasis. Topical roflumilast 0.3% cream (Zorvye™) was approved by the FDA in 2022 for the …

Dec 22, 2023 · Abstract Psoriasis is a common chronic immune-mediated disease with many comorbidities and impacts on quality of life. Among the treatments for psoriasis, phosphodiesterase …

Topical roflumilast cream is a highly potent, selective PDE4 inhibitor in a convenient, once-daily formulation that Arcutis is studying in a range of inflammatory skin diseases, including atopic …

Dec 19, 2023 · Apremilast is an oral PDE4 inhibitor for patients 18 years or older with plaque psoriasis, whereas roflumilast cream is a topical PDE4 inhibitor for patients 6 years or older.

Aug 30, 2025 · Topical roflumilast is another PDE-4 inhibitor approved by the FDA in 2022 for moderate-to-severe plaque psoriasis in adolescents and adults [11]. Several clinical trials have been carried …

Dermatologists Drs Neal Bhatia and Dr Leon Kircik discuss topical treatments and how recent approval of a novel topical PDE4 inhibitor is likely to impact the treatment landscape of plaque psoriasis.

Jul 13, 2023 · Roflumilast is a non-steroidal topical cream that was FDA approved for the treatment of plaque psoriasis in 2022. 1 Roflumilast selectively inhibits phosphodiesterase-4 (PDE-4), which is an …

Apr 20, 2020 · PDE4 inhibitors are a new type of treatment for plaque psoriasis that prevents inflammation. Here's what you need to know.

Abstract Phosphodiesterase-4 (PDE4) is involved in the synthesis of inflammatory cytokines that mediate several chronic inflammatory disorders, including psoriasis and atopic dermatitis. In recent …

May 7, 2024 · PDE-4 inhibitors, like apremilast, treat psoriasis by reducing inflammation and suppressing the immune response, improving skin symptoms.